Royalty Pharma (Royalty Pharma) Debt-to-Equity

: 0.94 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Royalty Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0 Mil. Royalty Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6,135 Mil. Royalty Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,526 Mil. Royalty Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.94.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Royalty Pharma's Debt-to-Equity or its related term are showing as below:

RPRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.94 Med: 1.22 Max: 1.45
Current: 0.94

During the past 7 years, the highest Debt-to-Equity Ratio of Royalty Pharma was 1.45. The lowest was 0.94. And the median was 1.22.

RPRX's Debt-to-Equity is ranked worse than
86.85% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs RPRX: 0.94

Royalty Pharma Debt-to-Equity Historical Data

The historical data trend for Royalty Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.02

1.21

1.23

1.26

0.94

Royalty Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.26	1.20	1.13	1.00	0.94

Competitive Comparison

For the Biotechnology subindustry, Royalty Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Debt-to-Equity falls into.

Royalty Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Royalty Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	6135.285)	/	6526.497
	=	0.94

Royalty Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	6135.285)	/	6526.497
	=	0.94

Royalty Pharma (NAS:RPRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Royalty Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (Royalty Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RPRX:Mexico RPD:Germany RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Executives

Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd	10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne	officer: EVP & CFO	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta	director, officer: CEO, Chairman of the Board	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd	officer: EVP, Investments & GC	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani	director, 10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic	10 percent owner	C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a.	10 percent owner	18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert	director	110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez	director	MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080